At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are assessing two different doses of revumenib to give with azacitidine and venetoclax in young people with leukemia. This study includes children, teens, and young adults with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that came back or keeps progressing after treatment.
-
Researchers want to find the best dose of INCB161734 to use in people with advanced cancer. The people in this study have solid tumors that have spread. In addition, their cancers have a genetic mutation (change) called KRAS G12D.
-
This purpose of this study is to assess two interventions to improve cancer care for older adults with cancer. Patients will be randomly assigned to one of the two interventions, which each consist of four surveys, five telephone sessions, and four subsequent "booster" calls with a licensed mental health counselor. The five telephone sessions each last about 45-60 minutes; the booster calls each last approximately 20-30 minutes. These surveys will include questions about each patient's illness, quality of life, depression, anxiety, and attitudes about aging and can be done via computer or over the phone. Patients will be compensated for their participation.
-
In this study, researchers want to find the highest dose of the investigational drug ORIC-944 that can be given safely in people with metastatic prostate cancer that continues to grow despite standard treatments. ORIC-944 works by blocking a group of proteins called PRC2, which promote prostate cancer growth. It is taken orally (by mouth).
-
Researchers want to find the best dose of ADCE-D01 to treat soft tissue sarcoma. In this study, we treat people with soft tissue sarcoma that is inoperable (cannot be surgically removed) or metastasized (spread).
-
Researchers want to learn if giving ivosidenib with other drugs is safe and works well in people with advanced cholangiocarcinoma. The people in this study have cholangiocarcinoma that has metastasized (spread) and is inoperable (cannot be removed with surgery). Their tumors have a mutation (change) in the IDH1 gene.
-
Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:
-
This protocol will provide expanded access to treatment with the investigational drug L-MTP-PE for people with osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system to kill cancer cells. L-MTP-PE is given intravenously (by vein).
- A Phase 1 Study of ANS03 in People With Advanced Solid Tumors
Full Title A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants with Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Purpose
Researchers want to find the best dose of ANS03 to use and see how well it works in people with solid tumors that metastasized (spread). In addition, their tumors have mutations (changes) in the ROS1 or NTRK1/2/3 genes.
This study includes people with these cancers:
- Non-small cell lung cancer
- Gastric (stomach) cancer
- Breast cancer
- Esophageal cancer
- Pancreatic cancer
- Other types of solid tumors
ANS03 blocks proteins (ROS1 and TRK) that may be too active or found at high levels in your cancer cells. By blocking these proteins, ANS03 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor that cannot be cured with standard therapy.
- Have a tumor with an ROS1 or NTRK1/2/3 gene fusion.
- Have completed prior anti-cancer therapies at least 4 weeks before getting ANS03.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-099Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06716138ClinicalTrials.gov
-
Researchers want to see how well datopotamab deruxtecan (Dato-DXd) works alone and with other drugs against cancer. The people in this study have endometrial, ovarian, or urothelial cancer that has metastasized (spread).